Page 178 - 2020_01-Haematologica-web

S. Kayser et al.
References
1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. WHO Press, Geneva, Switzerland, 2017.
2. Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initia- tive for rare ‘poor prognosis’ myeloid malignancies. Leukemia. 2006;20(7):1295- 1297.
3. Rowley JD and Potter D. Chromosomal banding patterns in acute nonlymphocytic leukemia. Blood.1976;47(5):705-721.
4. von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol. 1992;12(4):1687- 1697.
5. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene. 2002;21(21):3422-3444.
6. Ageberg M, Drott K, Olofsson T, et al. Identification of a novel and myeloid spe- cific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis. Genes Chromosomes Cancer. 2008;47(4):276-287.
7. Boer J, Bonten-Surtel J, Grosveld G. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol. 1998;18(3):1236- 1247.
8. Oancea C, Rüster B, Henschler R, et al. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopu- lating hematopoietic stem cells for leuke- mogenic transformation. Leukemia. 2010; 24(11):1910-1919.
9. Oyarzo MP, Lin P, Glassman A, et al. Acute myelogenous leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of FLT3 gene muta- tions. Am J Clin Pathol. 2004;122(3):348- 358.
10. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
11. Chi Y, Lindgren V, Quigley S, Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med. 2008;132(11):1835-1837.
12. Gupta M, Ashok Kumar J, Sitaram U, et al. The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genet Cytogenet. 2010;203(2):297-302.
13. Sandahl JD, Coenen EA, Forestier E, et al. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an internation- al study of 62 patients. Haematologica. 2014;99(5):865-872.
14. Tarlock K, Alonzo TA, Moraleda PP, et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor out- come in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br J Haematol. 2014;166(2):254-259.
15. Grimwade D, Hills RK, Moorman AV, et al.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
16. O'Donnell MR, Tallman MS, Abboud CN, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926-957.
17. Ishiyama K, Takami A, Kanda Y, et al. Allogeneic hematopoietic stem cell trans- plantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia. 2012;26(3):461-464.
18. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-464.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classifica- tion of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620- 625.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
21. Mitelman F: ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
22. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is pref- erentially seen in acute myeloid leukemia and myelodysplastic syndrome among var- ious hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11(10):1605-1609.
23. Schaich M, Röllig C, Soucek S, et al. Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011; 29(19):2696-2702.
24. Schaich M, Parmentier S, Kramer M, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitox- antrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31(17):2094-2102.
25. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598-605.
26. Burnett AK, Russell NH, Culligan D, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol. 2012;158(4):519-522.
27. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878- 3885.
years: results of the ALFA-9801 study. J Clin
Oncol. 2010;28(5):808-814.
29. Thomas X, Elhamri M, Raffoux E, et al.
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consoli- dation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011;118(7):1754-1762.
30. Thomas X, de Botton S, Chevret S, et al. Randomized phase II study of clofarabine- based consolidation for younger adults with acute myeloid leukemia in first remis- sion. J Clin Oncol. 2017;35(11):1223-1230.
31. Schemper M, Smith TL. A note on quanti- fying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
32. Kaplan E, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
33. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972; 34(2):187-220.
34. Mantel N, Byar D. Evaluation of response- time data involving transient states: An illustration using heart transplant data. J Am Stat Assoc. 1974;69(345):81-86.
35. Andersen P, Gill RD. Cox’s regression model for counting processes: A large sam- ple study. Ann Stat. 1982;10(4):1100-1120.
36. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non- responder bias. Stat Med. 1984;3(1):35-44.
37. Gray RJ. A class of k-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141- 1154.
38. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
39. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2014.
40. Knapper S, Russell N, Gilkes A, et al. A ran- domized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood. 2017;129(9):1143-1154.
41. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075.
42. Beya MD, Labopin M, Maertens J, et al. Allogeneic stem cell transplantation in acute myeloid leukemia with t(6;9)(p23;q34);dek-NUP214 is followed by a low relapse risk and favorable outcome in early phase- a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood. 2017; 130(Suppl 1):596.
43. Heinssmann M, Drangmeister L, Schmid K, et al. T(6;9)-DEK/CAN-positive leukemia: role of FLT3-ITD for the determination of the leukemic phenotype. Blood. 2012; 120(21):1316.
44. Kayser S and Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limita- tions. Leuk Lymphoma. 2014;55(2):243-
28. Pautas C, Merabet F, Thomas X, et al. 255.
Randomized study of intensified anthracy- cline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70
45. Thiede C, Bloomfield CD, Lo Coco F, et al. The high prevalence of FLT3-ITD muta- tions is associated with the poor outcome in adult patients with t(6;9)(p23;q34) posi-
168
haematologica | 2020; 105(1)